The civic record
Read. Follow. Verify.Securing America’s Drug Supply from Communist China Act
Last action · April 16, 2026: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Sponsors: Tom Cotton and 1 other
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
This bill requires the Department of Health and Human Services to review pharmaceutical companies with ties to the Chinese government, Communist Party, or military. It mandates the denial of new drug applications from these entities and authorizes the destruction of their imported drugs, unless a waiver is granted to prevent drug shortages.
This bill could restrict the availability of certain medications in the U.S. by banning imports from pharmaceutical companies affiliated with the Chinese government, unless those companies divest or sever ties.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Pharmaceutical companies with Chinese government ties
These entities face potential denial of new drug applications and the destruction of their imported products.
U.S. patients
Patients may experience changes in the availability of specific medications if their manufacturers are subject to import bans.
Key Facts
- The Secretary of Health and Human Services must review all new drug applications from Chinese entities to determine if they are affiliated with the Chinese government, Communist Party, or military.
- New drug applications from identified affiliated entities will be denied approval.
- The Secretary must retroactively review drug applications submitted between January 1, 2016, and the date of the bill's enactment.
- Drugs imported by identified affiliated entities will be refused entry and destroyed by U.S. Customs and Border Protection.
Show all 7 facts
- Affiliated entities have 180 days to sell their approved drug applications to non-affiliated entities to avoid import bans.
- The Secretary may waive import bans if the refusal would create or worsen a drug shortage in the United States.
- The bill authorizes $5,000,000 in appropriations to implement these review and enforcement processes.
Frequently Asked Questions
Will this bill cause my medication to be unavailable?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
2 actions- Apr 16, 2026SenateCommitteeRead twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Apr 16, 2026SenateIntroducedIntroduced in Senate
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Retroactive Regulatory Review
The bill mandates a look-back period of over 10 years (starting January 1, 2016) for existing drug applications, which is an unusually long window for regulatory review.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy75Intensity of disagreement among stakeholders
- Entertainment20Compellingness for a non-policy-wonk reader
- Buzz40Current news / social attention level
Publisher tools